

Innovation all for the patients



Roche A member of the Roche group

Roche Announces an Update on COVACTA Study for Chugai's Actemra for the Treatment of COVID-19

TOKYO, July 29, 2020 -- [Chugai Pharmaceutical Co., Ltd.](#) (TOKYO: 4519) announced today that Roche issued a press release regarding the update of COVACTA study of Actemra®/RoActemra®, a humanized anti-human IL-6 receptor monoclonal antibody [generic name: tocilizumab (genetical recombination)] created by Chugai for the treatment of COVID-19.

Please refer to the link below for details of the press release:

Roche provides an update on the phase III COVACTA trial of Actemra/RoActemra in hospitalised patients with severe COVID-19 associated pneumonia

<https://www.roche.com/media/releases/med-cor-2020-07-29.htm>

Trademarks used or mentioned in this release are protected by laws.

###